MISSISSAUGA, ON, Feb. 17,
2023 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, will release its Q1 Fiscal 2023 financial
results on Thursday, February 23,
2023, before markets open. A conference call and webcast to
discuss the financial results will be held on Thursday, February 23, 2023, at 9:00am EST.
To view, listen to, and participate in the live webcast, please
follow the link below:
https://app.webinar.net/gJazX3a59pK
To listen and participate via the conference call, please
dial:
North American Toll-Free: 1-888-664-6392
Local (Toronto): 416-764-8659
Confirmation Number: 23219091
Alternatively, please follow the link below and specify your
phone number in order to receive a call and be placed into the
conference call:
https://bit.ly/3W4uTEw
Participants will be able to ask questions of Company management
during the Q&A portion of the conference call either by asking
them on the call or by submitting them using the chat function on
the webcast.
A recording of the call will be available by calling
1-888-390-0541 or 416-764-8677 and entering the encore replay entry
code 219091# until March 9, 2023. A
recording of the call will also be available on www.covalon.com
under News & Events on the Investors tab.
Copies of Covalon's financial statements and MD&A can be
obtained on SEDAR at www.sedar.com and under Sedar Filings on
the Invest tab of Covalon's website.
For those interested in learning more about Covalon's solutions,
visit www.covalon.com or follow Covalon on LinkedIn, Facebook,
Instagram or Twitter.
Website: https://covalon.com/
Twitter: @covalon
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention and medical device
coatings, we offer innovative, gentler and more compassionate
options for patients to heal with less infections, less pain and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon's name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" or variations of such words and
phrases or state that certain actions, events or results "may",
"could", "would", "might", "will" or "will be taken", "occur" or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for year
ended September 30, 2022, which is
available on the Company's profile at www.sedar.com,
any of which could cause results, performance, or achievements to
differ materially from the results discussed or implied in the
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The forward-looking
statements contained in this news release are made as of the date
of this news release, and the Company assumes no obligation to
update or alter any forward-looking statements, whether as a result
of new information, further events or otherwise, except as required
by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-announces-conference-call-to-discuss-first-quarter-fiscal-2023-financial-results-301750283.html
SOURCE Covalon Technologies Ltd.